RayKnowChina Research Map
Shortlist

ShanghaiTongji University

Shanghai East Hospital, Tongji University

同济大学附属东方医院

Listed for 16 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shanghai East Hospital, Tongji University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌1 paper led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌13 papers led
  3. Hepatocellular carcinoma肝细胞癌36 papers led
  4. Stomach cancer胃癌37 papers led
  5. Retinoblastoma视网膜母细胞瘤0 papers led
  6. Chordoma脊索瘤1 paper led
  7. Osteosarcoma骨肉瘤2 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  9. Neuroblastoma神经母细胞瘤2 papers led
  10. Ewing sarcoma尤文肉瘤1 paper led
  11. Multiple myeloma多发性骨髓瘤13 papers led
  12. Fanconi anaemia范可尼贫血1 paper led
  13. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  14. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led1 open trial led
  15. IgA nephropathyIgA 肾病1 paper led
  16. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Hepatoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 1 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

10 hospitals in Shanghai for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06194656

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led1
  1. Diagnostic difficulties in muscular tuberculosis coexistent with nasopharyngeal carcinoma.2022Japanese journal of clinical oncology
All its trials on ClinicalTrials.gov, any status3
  1. Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell CarcinomaRecruitingNCT06194656Study sitePhase 2Start 2024-09
  2. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  3. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
More papers found outside PubMed (not counted)7
  1. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.2025Journal of Clinical Oncologyarticle
  2. LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv2025Annals of Oncologyconference-abstract
  3. Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study.2024Journal of Clinical Oncologyconference-abstract
  4. 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma2023Annals of Oncologyarticle
  5. A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).2023Journal of Clinical Oncologyconference-abstract
  6. Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer harboring FGF/FGFR gene aberrations.2022Journal of Clinical Oncologyconference-abstract
  7. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 13 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 5520232024: 4420242025: 222025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led13
  1. PADI4 facilitates stem-like properties and cisplatin resistance through upregulating PRMT2/IDs family in oesophageal squamous cell carcinoma.2025Clinical and translational medicineFree full text
  2. TRIM21 promotes K63-linked ubiquitination of ALKBH5 and suppresses cuproptosis via down-regulation of LIAS in esophageal squamous cell carcinoma.2025Communications biologyFree full text
  3. ELF4 contributes to esophageal squamous cell carcinoma growth and metastasis by augmenting cancer stemness via FUT9.2024Acta biochimica et biophysica SinicaFree full text
  4. STK3 kinase activation inhibits tumor proliferation through FOXO1-TP53INP1/P21 pathway in esophageal squamous cell carcinoma.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  5. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study.2024Nature medicineRCT
  6. The activation of asparagine synthetase by the transcription factor FOXM1 plays a pivotal role in the initiation and progression of ESCC.2024The journal of gene medicine
  7. TAOK3 Facilitates Esophageal Squamous Cell Carcinoma Progression and Cisplatin Resistance Through Augmenting Autophagy Mediated by IRGM.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  8. Intramedullary spinal cord metastasis from esophageal squamous cell carcinoma: case report and literature review.2023BMC neurologyFree full text
  9. Transcription factor 3 promotes migration and invasion potential and maintains cancer stemness by activating ID1 expression in esophageal squamous cell carcinoma.2023Cancer biology & therapyFree full text
  10. Homeobox A7 promotes esophageal squamous cell carcinoma progression through C-C motif chemokine ligand 2-mediated tumor-associated macrophage recruitment.2023Cancer scienceFree full text
  11. Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia.2023Journal of experimental & clinical cancer research : CRFree full text
  12. ETV5 overexpression promotes progression of esophageal squamous cell carcinoma by upregulating SKA1 and TRPV2.2022International journal of medical sciencesFree full text
  13. RIPK1 contributes to cisplatin-induced apoptosis of esophageal squamous cell carcinoma cells via activation of JNK pathway.2021Life sciences
All its trials on ClinicalTrials.gov, any status4
  1. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  2. A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Study sitePhase 1Start 2024-03
  3. A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Active, not recruitingNCT05094336Study sitePhase 1/Phase 2Start 2022-02
  4. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
More papers found outside PubMed (not counted)4
  1. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figsharedataset
  2. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  3. The construction of ceRNA prognostic regulatory network for ESCA by weighted gene co-expression network analysis and tumor-infiltrating immune cell analysis2022Research Squarepreprint
  4. CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 36 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
36
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 6620212022: 4420222023: 6620232024: 121220242025: 662025

15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    First in Human Study of SIM0610 in Solid Tumors
    Phase
    Phase 1
    Started
    2026-01
    Registry
    NCT07348211

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang

  2. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  3. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  4. Not yet recruiting
    Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07558200

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  5. Not yet recruiting
    A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06724263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersMedical oncologyRadiation oncologyGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led36
  1. Reverse Lipid Droplet Function for Hepatocellular Carcinoma Immunotherapy.2026Angewandte Chemie (International ed. in English)
  2. S-adenosylmethionine and nicotinic acid suppress Hepatocellular carcinoma proliferation by targeting SLC25A4.2026Biochemical pharmacology
  3. Natural Killer Cell-Associated Radiogenomics Model for Hepatocellular Carcinoma: Integrating CD2 and Enhanced CT-Derived Radiomics Signatures.2025Academic radiology
  4. HMGB1 orchestrates tumor-osteoclast crosstalk to drive bone metastasis in hepatocellular carcinoma.2025Cell death & diseaseFree full text
  5. PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma.2025Cell death & diseaseFree full text
  6. Clinical Significance of Acyl-CoA Dehydrogenase Short Chain and Its Anti-tumor Role in Hepatocellular Carcinoma by Inhibiting Canonical Wnt/β-Catenin Pathway.2025Digestive diseases and sciences
  7. Development of a prognostic model for hepatocellular carcinoma based on microvascular invasion characteristic genes by spatial transcriptomics sequencing.2025Frontiers in immunologyFree full text
  8. CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells.2025Journal of advanced researchFree full text
  9. Oncofetal MCB1 Is a Functional Biomarker for HCC Personalized Therapy.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  10. Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets.2024BMC cancerFree full text
  11. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer.2024Cancer immunology, immunotherapy : CIIFree full text
  12. WNK1 Interaction with KEAP1 Promotes NRF2 Stabilization to Enhance the Oxidative Stress Response in Hepatocellular Carcinoma.2024Cancer research
  13. Circ-0044539 promotes lymph node metastasis of hepatocellular carcinoma through exosomal-miR-29a-3p.2024Cell death & diseaseFree full text
  14. The Added Value of Contrast-Enhanced 68 Ga-FAPI-04 PET/MRI Over 18 F-FDG PET/CT in Hepatocellular Carcinoma.2024Clinical nuclear medicine
  15. A prognostic model for hepatocellular carcinoma patients based on polyunsaturated fatty acid-related genes.2024Environmental toxicology
  16. Models of fibrolamellar carcinomas, tools for evaluation of a new era of treatments.2024Frontiers in immunologyFree full text
  17. HMGB2 drives tumor progression and shapes the immunosuppressive microenvironment in hepatocellular carcinoma: insights from multi-omics analysis.2024Frontiers in immunologyFree full text
  18. METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma.2024Journal of hematology & oncologyFree full text
  19. Target prediction and potential application of dihydroartemisinin on hepatocarcinoma treatment.2024Naunyn-Schmiedeberg's archives of pharmacology
  20. Identification of shared and disease-specific intratumoral microbiome-host gene associations in gastrointestinal tumors.2024Physiological genomics
  21. Comprehensive analysis of KLF2 as a prognostic biomarker associated with fibrosis and immune infiltration in advanced hepatocellular carcinoma.2023BMC bioinformaticsFree full text
  22. High USP32 expression contributes to cancer progression and is correlated with immune infiltrates in hepatocellular carcinoma.2023BMC cancerFree full text
  23. Pan-cancer analysis of the oncogenic role of HNRNPR in human tumors.2023Cell biology international
  24. Metformin reduces hepatocarcinogenesis by inducing downregulation of Cyp26a1 and CD8+ T cells.2023Clinical and translational medicineFree full text
  25. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.2023Gastroenterology
  26. PIAS3 promotes ferroptosis by regulating TXNIP via TGF-β signaling pathway in hepatocellular carcinoma.2023Pharmacological research
  27. Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma.2022Cell death & diseaseFree full text
  28. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.2022Cellular oncology (Dordrecht, Netherlands)Free full text
  29. Identification of a Prognostic Transcriptome Signature for Hepatocellular Carcinoma with Lymph Node Metastasis.2022Oxidative medicine and cellular longevityFree full text
  30. ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis.2022Stem cell research & therapyFree full text
  31. Molecular characterization of long-term survivors of hepatocellular carcinoma.2021AgingFree full text
  32. Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients.2021BMC cancerFree full text
  33. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma.2021Bioscience reportsFree full text
  34. Targeting p300/CBP Attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism.2021Cancer research
  35. Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy.2021International journal of biological sciencesFree full text
  36. CD63 negatively regulates hepatocellular carcinoma development through suppression of inflammatory cytokine-induced STAT3 activation.2021Journal of cellular and molecular medicineFree full text
All its trials on ClinicalTrials.gov, any status9
  1. First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Study sitePhase 1Start 2026-01
  2. Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid TumorsNot yet recruitingNCT07558200Study sitePhase 1Start 2026-05
  3. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Study sitePhase 2Start 2025-05
  4. A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsNot yet recruitingNCT06724263Study sitePhase 2Start 2024-12
  5. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  6. A Phase I/II Study of AST-3424 in Subjects With Advanced Solid TumorsActive, not recruitingNCT06239155Study sitePhase 1/Phase 2Start 2019-09
  7. A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular CarcinomaCompletedNCT04194801Study sitePhase 1/Phase 2Start 2019-12
  8. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  9. An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular CarcinomaStatus unknownNCT03439761Study sitePhase 1/Phase 2Start 2018-03

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 37 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
37
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 4420212022: 6620222023: 9920232024: 8820242025: 10102025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Registry
    NCT07221149

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Nanning, Shanghai

  2. Recruiting
    SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT06123494

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  3. Recruiting
    A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
    Phase
    Phase 2
    Started
    2023-07
    Registry
    NCT05934331

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  4. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseEarly detection & endoscopySurgery
Departments in papersGastroenterology / hepatologyMedical oncologySurgery (general/hepatobiliary/pancreatic)Radiation oncology
Papers it led37
  1. The Value of Primary Tumor Resection in Patients with Liver Metastases: A 10-Year Outcome.2025Annals of surgical oncologyFree full text
  2. Short-term endoscopic alterations of early gastric cancer after successful eradication of Helicobacter pylori.2025BMC gastroenterologyFree full text
  3. Clinical Characteristics and Pathological Features of "Crawling-type" Early Gastric Carcinoma: A Retrospective Series of Eight Cases.2025Cancer control : journal of the Moffitt Cancer CenterFree full text
  4. TRIM8-dependent K63-ubiquitinated PGK1 promotes glycolysis and angiogenesis in gastric cancer via interaction with ACAT1.2025Cell death & diseaseFree full text
  5. Endoscopic Full-Thickness Resection vs Submucosal Tunneling Endoscopic Resection for Gastric Submucosal Tumors.2025Clinical and translational gastroenterologyFree full text
  6. Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial.2025European journal of cancer (Oxford, England : 1990)
  7. C15orf39, a downstream effector of PI3K/AKT signaling, promotes gastric carcinogenesis and correlates with patient outcomes.2025International journal of biological macromolecules
  8. TRIM32 promotes tumor immune evasion and impedes Anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer.2025Journal of translational medicineFree full text
  9. Uncut Roux-en-Y for very small remnant stomach in gastric cancer: surgical advantages and nutritional outcomes.2025Surgical endoscopy
  10. Therapeutic value of dissecting stations 1 and 4Sb lymph nodes during radical distal gastrectomy for lower- and middle-third gastric cancer.2025World journal of surgical oncologyFree full text
  11. Lipid levels and insulin resistance markers in gastric cancer patients: diagnostic and prognostic significance.2024BMC gastroenterologyFree full text
  12. LncRNA PCED1B-AS1 mediates miR-3681-3p/MAP2K7 axis to promote metastasis, invasion and EMT in gastric cancer.2024Biology directFree full text
  13. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer.2024Cancer immunology, immunotherapy : CIIFree full text
  14. A new tandem repeat-enriched lncRNA XLOC_008672 promotes gastric carcinogenesis by regulating G3BP1 expression.2024Cancer scienceFree full text
  15. The role of mir96 in predicting CTC status and prognostic evaluation in gastric cancer patients.2024Cellular and molecular biology (Noisy-le-Grand, France)
  16. A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer.2024Med (New York, N.Y.)RCT
  17. Peptidylprolyl isomerase A guides SENP5/GAU1 DNA-lncRNA triplex generation for driving tumorigenesis.2024Nature communicationsFree full text
  18. Identification of shared and disease-specific intratumoral microbiome-host gene associations in gastrointestinal tumors.2024Physiological genomics
  19. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.2023BMC medicineFree full text
  20. CircRNA_15430 reduced by Helicobacter pylori infection and suppressed gastric cancer progression via miR-382-5p/ZCCHC14 axis.2023Biology directFree full text
  21. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/MRI in the Preoperative Diagnosis of Gastric Cancer.2023Canadian journal of gastroenterology & hepatologyFree full text
  22. No-touch endoscopic full-thickness resection technique for gastric gastrointestinal stromal tumors.2023Endoscopy
  23. Novel KDM2B/SAV1 Signaling Pathway Promotes the Progression of Gastric Cancer.2023Genetics researchFree full text
  24. Superficial Flat-Type Early-Stage Gastric Signet Ring Cell Carcinoma in the Atrophic Background Mucosa: Two Case Reports.2023Journal of gastrointestinal cancer
  25. TGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer.2023Pharmaceutical research
  26. Application of a New Retraction Method in Laparoscopic Gastrectomy for Gastric Cancer.2023Surgical laparoscopy, endoscopy & percutaneous techniques
  27. Improvement of esophagojejunostomy technique after total gastrectomy with overlap method: reduce the difficulty of surgery and shorten operation time.2023Updates in surgery
  28. The Modified Glasgow Prognostic Score Predicts Survival in Gastric Cancer Patients with Normal CEA and CA19-9.2022Canadian journal of gastroenterology & hepatologyFree full text
  29. Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating With the Response to Immunotherapy in Patients With Gastric Cancer.2022Frontiers in immunologyFree full text
  30. LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  31. The Role of Alternative Splicing Factors, DDB2-Related Ageing and DNA Damage Repair in the Progression and Prognosis of Stomach Adenocarcinoma Patients.2022GenesFree full text
  32. Submucosal Tunneling Endoscopic Resection for Submucosal Tumors in the Proximal Esophagus.2022Journal of the American College of Surgeons
  33. Transcriptome Profiling Analysis Identifies LCP1 as a Contributor for Chidamide Resistance in Gastric Cancer.2022Pharmaceutical research
  34. Trifunctional Graphene Quantum Dot@LDH Integrated Nanoprobes for Visualization Therapy of Gastric Cancer.2021Advanced healthcare materialsFree full text
  35. Circular RNA hsa_circ_0000117 accelerates the proliferation and invasion of gastric cancer cells by regulating the microRNA-337-3p/signal transducer and activator of transcription 3 axis.2021BioengineeredFree full text
  36. Overexpression of NELFE contributes to gastric cancer progression via Wnt/β-catenin signaling-mediated activation of CSNK2B expression.2021Journal of experimental & clinical cancer research : CRFree full text
  37. Exploration of endoscopic findings and risk factors of early gastric cancer after eradication of Helicobacter pylori.2021Scandinavian journal of gastroenterology
Chinese-language papers (not in the count)1
  1. [Effects of gastrectomy on quality of life of patients with gastric cancer and its evaluation methods].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status24
  1. Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric CancerStatus unknownNCT06078982Lead sponsorPhase 1Start 2023-06
  2. Water-injecting Endoscopic Submucosal Dissection for Early Gastric Cancer: a Retrospective Cohort StudyCompletedNCT07244471Lead sponsorStart 2019-01
  3. Submucosal Pressure Ejection Endoscopic Dissection for Early Gastric Cancer: a Retrospective Cohort StudyCompletedNCT07453433Lead sponsorStart 2019-01
  4. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)RecruitingNCT07221149Study sitePhase 2/Phase 3Start 2026-03
  5. SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing RegimenRecruitingNCT06123494Study sitePhase 3Start 2024-01
  6. A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingNCT05934331Study sitePhase 2Start 2023-07
  7. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  8. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  9. A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Active, not recruitingNCT05094336Study sitePhase 1/Phase 2Start 2022-02
  10. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  11. Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric CancerStatus unknownNCT04908813Study sitePhase 2Start 2021-09
  12. Efficacy and Safety of Remimazolam Tosylate for Sedation in GastroscopyStatus unknownNCT04727034Study siteN/AStart 2021-03
  13. A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing TumorsCompletedNCT04513223Study sitePhase 1Start 2021-03
  14. Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric CancerActive, not recruitingNCT04725994Study sitePhase 1/Phase 2Start 2021-06
  15. IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ AdenocarcinomaCompletedNCT05327231Study sitePhase 1Start 2020-07
  16. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid TumorsCompletedNCT04400383Study sitePhase 1Start 2020-06
  17. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  18. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  19. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT04053205Study sitePhase 1/Phase 2Start 2019-11
  20. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  21. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  22. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  23. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)CompletedNCT03399110Study sitePhase 3Start 2018-01
  24. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Shanghai for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

15 hospitals in Shanghai for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Primary Ewing's sarcoma of the uterine cervix: a case report and review of the literature.2024Journal of cancer research and clinical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 13 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.8%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 6620232024: 4420242025: 222025

16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDrug combinationsRelapse & resistanceDiagnosis, MRD & risk

Over half of these papers are lab or animal studies.

Papers it led13
  1. Aberrant activation of adenine nucleotide translocase 3 promotes progression and chemoresistance in multiple myeloma dependent on PINK1 transport.2025International journal of biological sciencesFree full text
  2. Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis.2025Journal of biomedical scienceFree full text
  3. EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma.2024Acta biochimica et biophysica SinicaFree full text
  4. Interference with PLA2G16 promotes cell cycle arrest and apoptosis and inhibits the reprogramming of glucose metabolism in multiple myeloma cells by modulating the Hippo/YAP signaling pathway.2024Anti-cancer drugsFree full text
  5. A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory.2024International immunopharmacology
  6. Construct prognostic models of multiple myeloma with pathway information incorporated.2024PLoS computational biologyFree full text
  7. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.2023Acta biochimica et biophysica SinicaFree full text
  8. A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.2023Acta biochimica et biophysica SinicaFree full text
  9. Molecular mechanism by which RRM2-inhibitor (cholagogue osalmid) plus bafilomycin A1 cause autophagic cell death in multiple myeloma.2023Archives of biochemistry and biophysics
  10. TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage.2023Cancer medicineFree full text
  11. The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.2023Journal of translational medicineFree full text
  12. Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma.2023Leukemia
  13. Predictive Value Analysis of Serum Ig A, Ig G, and TNF-α in Recurrence of Multiple Myeloma.2022Disease markersFree full text

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Shanghai for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Papers it led1
  1. Diagnosis and Management of Fanconi Anemia.2025Journal of evidence-based medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025

34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

17 hospitals in Shanghai for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)
    Phase
    N/A
    Started
    2024-03
    Registry
    NCT06765564

    Age 18 years to 60 years (registered criteria)

    Led by Shanghai East Hospital, Tongji University; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Endoscopic diagnosis, treatment and evaluation of iatrogenic biliary stricture].2023Zhonghua yi xue za zhi

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

同济大学附属东方医院

Shanghai East Hospital, Tongji University

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Shanghai East Hospital; East Hospital; Shanghai East Hospital (East Hospital Affiliated to Tongji University); East Hospital of Tongji University; Research Center for Translational Medicine at Shanghai East Hospital; East Hospital Affiliated to Tongji University in Shanghai; Research Center for Translational Medicine at East Hospital; Shanghai East Hospital Ji'an hospital

Suggest a correctionDownload the data